(Total Views: 219)
Posted On: 03/19/2019 1:38:02 PM
Post# of 154361
Thanks for the info and reference Fortuno! That is more discouraging than I had hoped.
So, if I understand these agreements correctly we will owe 'up to' 12.5% of net sales. How is the 'up to' determined? If there is no cap to the sales amount, ABBV and PGNX may end up making more from leronlimab than CytoDyn??
I hope I am not familiar enough with these agreements and misunderstanding something.
So, if I understand these agreements correctly we will owe 'up to' 12.5% of net sales. How is the 'up to' determined? If there is no cap to the sales amount, ABBV and PGNX may end up making more from leronlimab than CytoDyn??
I hope I am not familiar enough with these agreements and misunderstanding something.
(0)
(0)
Please do your own due diligence. All my posts and comments are not to be considered investment advice.
